image

Japan Country Report

Presented by

Discovery Reports

Denka Seiken promotes public health with early detection kits

Japanese manufacturer developed point-of-care testing kits for Ebola epidemic in 2014 and is also a leading name in influenza vaccines

PUBLISHED : Wednesday, 13 April, 2016, 2:41pm
UPDATED : Wednesday, 13 April, 2016, 5:46pm

Country Business Reports interviews and articles by Discovery Reports www.discoveryreports.com

Early detection makes a huge impact in treating and managing diseases. This is the mindset that Denka Seiken cultivates with its point-of-care testing (POCT) kits, which are designed to deliver results in a shorter time frame. In China and other massive markets, Denka Seiken aims to raise awareness on how products such as the QuickNavi-Flu influenza antigen detection kit can help prevent pandemics and, in turn, save lives.

“If patients are not properly treated, their illnesses will worsen and pose a threat to public health,” says president Tetsuro Maeda.

When the Ebola epidemic in West Africa gripped the world in fear in 2014, Denka Seiken rose to the occasion and developed a POCT kit for early Ebola detection. Awaiting the approval of the World Health Organisation, the company will donate the product for public use.

Prior to its expansion into diagnostic reagents, Denka Seiken had established itself as a leading name in influenza vaccines. In addition, with a 33 per cent market share in Japan for the influenza POCT kits, the leading manufacturer has dedicated itself to eradicating infectious diseases.

As lifestyles evolve, viruses and bacteria are not the only culprits behind illnesses. Diet also negatively impacts overall health.

Denka Seiken has developed diagnostic reagents that are compatible with general-purpose autoanalysers to easily measure high- and low-density lipoprotein cholesterol, among others. Its Chinese local partner obtained approval last month from the China Food and Drug Administration for a small dense low-density lipoprotein, or sdLDL, a heart-failure risk marker variant. Denka Seiken expects that the assay’s approval will help demonstrate its clinical significance and promote its recognition throughout the mainland.

Bullish on its outlook for Asia, Denka Seiken targets to achieve 1.6 times sales growth in five years. This figure will be driven by the company’s continuous expansion into new business areas such as researching into tropical infectious diseases including dengue and malaria.

 

Denka Seiken
http://www.denka-seiken.jp